Sanofi’s first short-acting insulin, Admelog receives FDA approval
Date: 2017-12-12   Author: Sunil Hebbalkar  Category: #news

Sanofi’s first short-acting insulin, Admelog receives FDA approval

The U.S. FDA has approved first short-acting insulin, Admelog to control increasing risk associated with diabetes. After several clinical trials on Admelog from September 2017, FDA has now granted the final approval to this diabetes treatment drug, which improves blood sugar levels in adults with type 2 diabetes, children aged 3 years, and the elderly with diabetes mellitus of type 1.

As per the estimates by CDC (Center for Disease Control and Prevention), more than 30 million people across the United States suffer from diabetes, which tends to increase the risk of serious health issues such as kidney damage, heart disease, blindness. The risk associated with these long-term complications can be reduced with insulin treatment, which seems to have been the base of the aforementioned discovery, as per sources.

Reliable reports state that the new drug approval application could be sanctioned through 505 (b)(2) pathway, commonly called as Federal Food, Drug, and Cosmetic Act. The new drug approval may also depend on FDA’s approval of similar drugs earlier. The use of such pathways is likely to reduce the overall development cost associated with products, which may be supplied to the patients at a lower cost, state sources.

The deputy director of FDA’s New Drug Evaluation II, Mary T. Thanh Hai has stated that they were approving a short-acting insulin drug for patients as per the required safety and effectiveness standards. The scientific data associated with Admelog includes two phase 3 clinical trials for which approximately 500 patients had enrolled.

Reports cite that in the clinical trials, the research team of FDA had found certain adverse reactions associated with the intake of Admelog such as rashes, itching, and hypoglycemia. Allergic reactions, thickening or thinning of fatty tissue, and adverse reactions at injection site are also other implications of Admelog, claims the FDA report.

Reportedly, caregivers and patients have been advised by the FDA to check the blood glucose level before being treated with insulin products, to prevent the onset of any other complication due to Admelog.



About Author


Sunil Hebbalkar

Sunil Hebbalkar

Sunil currently works as an content writer at AlgosOnline. A Post graduate mechanical design engineer by qualification, he worked as an intern at the defense lab for one year in the engine design and development department before switching his professional genre. Foll...

Read More

More from Sunil


Post Recommendents

Energy startup RigUp raises $300 million in Series D investment round
Author: Saipriya Iyer

Austin has been witnessing substantial investments in its technology market landscape since 2018. The city has witnessed a surged in its venture capital activities, in technology startups, since the start of 2019. Tech...


BASIX Sub-K manages to raise Rs 75 Cr from its Series-C funding round
Author: Paroma Bhattacharya

Fintech companies are known for managing various monetary services using technology. The industry is witnessing several new smaller companies and startups who are bringing various innovative schemes and models. However...


Pennsylvania American Water buys assets of Steelton Borough Authority
Author: Pankaj Singh

In 2016, a law was passed in Pennsylvania which made in feasible for water authorities to sell their assets to utility companies. Since then, the Pennsylvania water service market has witnessed a substantial growth as ...